Parkinson’s disease is a chronic neurodegenerative disease characterized by progressively worsening motor symptoms. Treatment of Parkinson’s disease in China comprises a broad range of symptomatic therapies including, dopamine precursors, dopamine agonists, MAO-B inhibitors, and COMT inhibitors. The expected imminent approval of safinamide—the third-to-market MAO-B inhibitor—and LY03003—the reformulation of rotigotine, a dopamine agonist, that offers a more convenient once-weekly dosing advantage—have the potential to meaningfully change the treatment paradigm of Parkinson’s disease in China. The uptake of these therapies, in addition to the growing aging-led prevalence of the disease in the country, will lead to significant growth of the Parkinson’s disease market of China during the 2021-2031 period. Additionally, in view of the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies will be increasingly encouraged to enter this market.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 neurologists
Epidemiology: Diagnosed prevalence of Parkinson’s disease in urban versus rural China; clinically relevant and market-relevant drug-treatable populations
Forecast: 10-year, annualized, drug-level sales and patient shares of key heart failure therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.